Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Grau Bartomeu J, Gallardo Martínez LJ, Olona Tabueña N, Moreno Oliver A and Vallès Callol JA
Background: The interaction between acenocoumarol and omeprazole is described to be possible in different forums even though the evidence shows that both can be prescribed together safely.
Aim: To evaluate the introduction of omeprazole on the effect of acenocoumarol in primary care clinical practice.
Design and setting: Cross-sectional study with prospective follow-up of the patients treated with acenocoumarol for 18 months period in 5 health urban areas.
Method: Association of age, sex, anticoagulant dose, indication and INR values according the use of acenocoumarol and PPI.
Results: Of the 260 patients with acenocoumarol (with 3,280 INR measurements) at the start, 126 (48.5%) had previously been with some PPI (97 took omeprazole, mean INR of 2.43), 134 patients were not taking any PPI at the start of the study. Of the patients not previously treated with a PPI, 52 started with some PPI during the monitoring period; in 47 cases the PPI was omeprazole, 33 (70.2%) of which had an INR within the therapeutic range just before the administration of omeprazole. After the administration of omeprazole, 30 patients (90.9%) remained within the therapeutic range. The mean INR values just before and after the administration of omeprazole were 2.47 and 2.46 respectively (P=0.814).
Conclusion: The addition of omeprazole to patients treated with acenocoumarol did not modify the INR values, reaffirming that there is no drug interaction. Long-term concomitant treatment with acenocoumarol and omeprazole is compatible with the INR measures within the target range.